Outlook Therapeutics Sees 615% Surge as FDA Fast-Tracks Eye Drug Review and Nasdaq Threat Fades

FDA accepts Lytenava application, boosting stock 600% and lifting Nasdaq delisting risk. Approval decision set for July 29, 2026.

Outlook Therapeutics has staged a remarkable recovery from penny-stock territory, with its share price rocketing more than 600% in the past month after the US Food and Drug Administration accepted its marketing application for the experimental eye drug Lytenava. The rally has not only boosted investor sentiment but also removed an existential risk: a potential delisting from the Nasdaq.

The stock closed at $1.67 on the day of the FDA announcement, up roughly 615% from its 30-day low of $0.16 in March. On a weekly basis, the gain was 88%, while the year-to-date advance stood at an eye-watering 153%. The surge lifted the shares comfortably above the $1 minimum bid price that the Nasdaq requires for continued listing. In February, the exchange had warned that the stock had traded below that threshold for too long, giving the company until mid-August to regain compliance. With the current level well above $1.60, Outlook Therapeutics now appears to have cleared that hurdle, provided it holds above $1 for ten consecutive trading days.

The catalyst for the rally was the FDA’s classification of the Lytenava application as a Class 1 review, which compresses the decision timeline to 60 days. The regulator has set a final action date of July 29, 2026. Importantly, the review has moved past clinical data disputes; the agency is now focused on final labeling discussions. If approved, Lytenava would become the first bevacizumab formulation specifically cleared for ophthalmic use in the US, targeting wet age-related macular degeneration.

Oversold No Longer?

The speed of the stock’s ascent has pushed technical indicators into extreme overbought territory. The relative strength index has hit 87, a level that historically precedes sharp pullbacks. Some traders may be tempted to take profits ahead of the FDA verdict, particularly given that the market has already priced in substantial regulatory optimism. The stock remains highly volatile, and any negative news could trigger a rapid reversal.

European Traction and Cash Constraints

Outside the US, Lytenava is already generating revenue. It has been launched in Germany and the UK, and a Swiss distribution agreement with Mediconsult is slated for 2027. Later this year, the company expects to add Ireland and the Netherlands to its commercial footprint. These markets provide a blueprint for a US rollout, but they have not yet alleviated the pressure on the balance sheet.

At the end of March, Outlook Therapeutics held just $7.7 million in cash. The company posted a net loss of $4.5 million for the quarter, while total cash burn—including operating and investing outflows—reached $14.1 million. Management has already turned to direct stock placements to shore up liquidity, and a fresh capital raise in April provided a temporary cushion. However, the risk of further dilution remains high, especially if the FDA decision is delayed or negative.

Countdown to July 29

All eyes are now on the FDA’s verdict. A green light would unlock the US market and make Lytenava the first approved bevacizumab eye formulation. It would also trigger the real commercial test: converting regulatory momentum into sales. Until then, the stock is a speculative play, with the July 29 deadline determining whether the recent rally is the start of a sustained uptrend or a spectacular pre-event spike destined to fade.